Search Results
Sep 09, 2026, 07:00 ET Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
mg participant with a 3-month PR had reached the 6-month assessment at data cutoff.All 3-month CRs with 6-month assessments remained in response at 6 months (n=5).The first participant in the study remained in CR at 12 months and continued
More news about: Tyra Biosciences
Sep 08, 2026, 09:00 ET IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
the 268 patients who experienced CRS, 73% had CRS after the first dose, 60% had CRS after the second dose, and 15% had CRS following the third or later dose. Following the Cycle 1 Day 1, Day 8, Day 15 infusions, 24%, 8%, and 1% of patients experienced Grade ≥ 2 CRS, respectively. From Cycle 2 onwards,
More news about: Amgen
Sep 08, 2026, 07:04 ET CITY OF CHICAGO PARTNERS WITH CHICAGO RIVER SWIM TO RE-LAUNCH "THE BIG JUMP," EXPAND FIELD TO 750 SWIMMERS
March 13 CRS Announcement |
More news about: A Long Swim
Sep 08, 2026, 07:04 ET DIE STADT CHICAGO ARBEITET MIT „CHICAGO RIVER SWIM" ZUSAMMEN, UM „THE BIG JUMP" NEU ZU STARTEN UND DIE TEILNEHMERZAHL AUF 750 SCHWIMMER ZU ERWEITERN
Ankündigung des CRS vom 13. März |
More news about: A Long Swim
Sep 08, 2026, 07:04 ET CITY OF CHICAGO PARTNERS WITH CHICAGO RIVER SWIM TO RE-LAUNCH "THE BIG JUMP," EXPAND FIELD TO 750 SWIMMERS
March 13 CRS Announcement |
More news about: A Long Swim
Sep 08, 2026, 07:04 ET LA CIUDAD DE CHICAGO SE ASOCIA CON CHICAGO RIVER SWIM PARA RELANZAR «THE BIG JUMP» Y AMPLIAR EL NÚMERO DE PARTICIPANTES A 750 NADADORES
Comunicado de CRS del 13 de marzo |
More news about: A Long Swim
Sep 08, 2026, 07:04 ET LA VILLE DE CHICAGO S'ASSOCIE À CHICAGO RIVER SWIM POUR RELANCER « THE BIG JUMP » ET PORTER LE NOMBRE DE PARTICIPANTS À 750 NAGEURS
Communiqué du CRS du 13 mars |
More news about: A Long Swim
Sep 08, 2026, 06:01 ET 페프로민 바이오, 기존 CD19 CAR T세포 치료 실패 포함 재발성/불응성 B세포 림프종에서 깊고 지속적인 완전관해 입증한 제1상 임상시험 결과 랜싯에 게재 발표
CAR'). 데이터 마감 시점까지 모든 완전관해가 지속됐으며 재발 사례는 관찰되지 않았다. 가장 오래 지속된 완전관해는 35개월에 달해 완치 가능성을 시사했다.PMB-CT01은 모든 사이토카인 방출 증후군(cytokine release syndrome, CRS) 사례와 보고된 2건의 면역효과세포 연관 신경독성 증후군(immune effector cell-associated neurotoxicity syndrome, ICANS) 사례가 모두 1등급에 그치는 등 매우 우수한 안전성을 보였다.이러한 유망한 결과를 바탕으로
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie
die Wahrscheinlichkeit einer Heilung hindeutet.PMB-CT01 erwies sich als bemerkenswert sicher, da alle Fälle des Zytokinfreisetzungssyndroms (CRS) und die beiden gemeldeten Fälle des Immuneffektorzell-assoziierten Neurotoxizitätssyndroms (ICANS) auf Grad 1 beschränkt waren.Aufgrund dieser
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
ongoing complete response reaching 35 months, suggesting the likelihood of cure.PMB-CT01 was remarkably safe, as all cytokine release syndrome (CRS) events and the two reported immune effector cell-associated neurotoxicity syndrome (ICANS) events were limited to Grade 1.Based on these promising
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
ongoing complete response reaching 35 months, suggesting the likelihood of cure.PMB-CT01 was remarkably safe, as all cytokine release syndrome (CRS) events and the two reported immune effector cell-associated neurotoxicity syndrome (ICANS) events were limited to Grade 1.Based on these promising
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio anuncia la publicación en The Lancet de los resultados de su ensayo clínico de fase 1
sugiere la probabilidad de curación.PMB-CT01 demostró una seguridad notable, ya que todos los eventos de síndrome de liberación de citoquinas (CRS) y los dos eventos de síndrome de neurotoxicidad asociado a células efectoras inmunitarias (ICANS) notificados se limitaron al grado 1.Basándose
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 03, 2026, 09:15 ET AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
ratio 0.40) versus investigator's choice of standard available therapies Etentamig demonstrated low rates of cytokine release syndrome (CRS) and fatal infections with monthly dosing (Q4W) from initiation following a single step-up dose Etentamig's dosing schedule and clinical
More news about: AbbVie
Sep 02, 2026, 06:18 ET Flyme AIOS to Deploy WorkBuddy AI Tools Across All Flyme Platforms
reports, presentations and code. Offering both local on‑device processing and always‑on secure cloud sandbox execution with CRS‑device sync, WorkBuddy serves 12 industries with 140+ AI advisors and 22,000+ skills and plugins.
More news about: ECARX Holdings Inc.
Aug 26, 2026, 16:33 ET Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
Group Holding Ltd (CRDO UW Equity), Casey's General Stores Inc. (CASY UW Equity), Sunbelt Rentals Holdings Inc. (SUNB UN Equity), Carpenter Technology (CRS UN Equity), Curtiss-Wright Corp. (CW UN Equity), ATI Inc. (ATI UN Equity), AerCap Holdings NV (AER UN Equity) and KeyCorp (KEY UN Equity).The
More news about: Bloomberg
Aug 24, 2026, 20:30 ET Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Aug 24, 2026, 12:26 ET Confluence Financial Partners Announces Strategic Partnership with Constellation Wealth Capital
certain level of skill or training. For additional information about the firm, including its services and fees, please refer to Form ADV Part 2A and Form CRS available at
More news about: Confluence Financial Partners
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These differentiated features support the platform's broad applicability across autoimmune diseases, solid tumors and hematological
More news about: Antengene Corporation Limited
Aug 18, 2026, 21:00 ET Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological malignancies
More news about: Antengene Corporation Limited
Aug 17, 2026, 08:00 ET OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
glycoform of CD24 (neoCD24) —— Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk —ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc.,
More news about: OncoC4
Aug 11, 2026, 08:00 ET Dominari Year to Date Revenue Increases by 14% Over 2025
the principal invested. You can check the background of Dominari Securities LLC and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings, Inc.
Aug 04, 2026, 09:00 ET Modera Wealth Management Expands New York Presence
www.adviserinfo.sec.gov) to obtain a copy of our disclosure statement, Form ADV Part 2A, and ADV Part 3/Form CRS. In addition, our Privacy Notice outlines how we handle your non-public personal information. Please read these documents carefully before you make a
More news about: Modera Wealth Management, LLC
Aug 03, 2026, 08:30 ET Dominari Congratulates Powerus on its Multimillion Dollar Contract for Aerial Drone System
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings, Inc.
Aug 03, 2026, 02:57 ET Motilal Oswal Financial Services Hosts the 10th Edition of Motilal Oswal Business Impact Conference - MOBIC
Managers and 7600+ external Wealth Managers. The business supports more than 1.5 million active clients with total assets under advice of Rs. 3.36+ Lakh Crs, delivering comprehensive wealth management solutions tailored to diverse client needs.
More news about: Motilal Oswal Financial Services Ltd
Jul 28, 2026, 09:00 ET Cowbell Launches OMNI, an AI-Native Decision Intelligence System Transforming Specialty Insurance
States, Australia, and the United Kingdom and is backed by more than 25 leading global (re)insurance partners. Through Cowbell Resiliency Services (CRS), policyholders gain access to cybersecurity advisory services, digital forensics and incident response capabilities, and proactive risk mitigation solutions
More news about: Cowbell Cyber, Inc.